Drug intelligence / Profile preview

Branchamin

Development stage: Phase 4
Lead developer: XiZang RenChuang Future Pharmaceutical Marketing
Modality: Small Molecules
Administration: Intravenous

Overview

Branchamin is a parenteral nutrition solution primarily composed of branched-chain amino acids, specifically L-leucine, L-isoleucine, and L-valine. It is administered intravenously to provide essential amino acids for protein synthesis and energy metabolism in patients who cannot receive adequate nutrition through oral or enteral routes. It is used to support nutritional metabolism, particularly in patients undergoing procedures like subtotal or total gastrectomy and pancreatectomy.

Brand names: BranchAmin
Other names: Branched-chain amino acidsBCAAL-isoleucine compound with L-leucine and L-valine (1:1:1)

Targets

SESN2 (Sestrin-2)BCKDH complex (Branched-chain alpha-keto acid dehydrogenase complex)BCAT (Branched-chain-amino-acid transaminase 1)

Beyond the preview

Go deeper on Branchamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Branchamin.

Explore the full profile